Analyst Price Targets — SLP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 18, 2026 11:16 am | — | Craig-Hallum | $18.50 | $18.25 | TheFly | Simulations Plus downgraded to Hold from Buy at Craig-Hallum |
| July 29, 2024 2:05 am | Scott Schoenhaus | KeyBanc | $47.00 | $39.70 | StreetInsider | KeyBanc Starts Simulations Plus (SLP) at Overweight |
| June 13, 2024 8:55 am | Matt Hewitt | Craig-Hallum | $56.00 | $49.60 | TheFly | Simulations Plus price target raised to $56 from $51 at Craig-Hallum |
| June 13, 2024 6:24 am | Francois Brisebois | Oppenheimer | $65.00 | $49.26 | StreetInsider | Simulations Plus (SLP) PT Raised to $65 at Oppenheimer |
| June 21, 2023 2:56 pm | Francois Brisebois | Oppenheimer | $67.00 | $48.07 | Benzinga | Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst |
Latest News for SLP
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active…
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally…
Shares of Simulations Plus, Inc. (NASDAQ: SLP - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $16.21 and traded as high as $18.42. Simulations Plus shares last traded at $18.42, with a volume of 104,375 shares. Wall Street Analysts Forecast Growth A
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration's (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLP.
U.S. House Trading
No House trades found for SLP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.